- The tumor necrosis factor alpha-inhibitor infliximab has been shown to be efficacious and offer an acceptable safety profile in the treatment of inflammatory autoimmune diseases.
- Biosimilar infliximab (Remsima®) gained marketing approval in Europe in 2013, based on a data package demonstrating the clinical equivalence of Remsima and reference infliximab (Remicade®).
- The annual drug-cost savings resulting from the introduction of Remsima were projected to range from €2.887 million (Belgium, 10% discount) to €33.798 million (Germany, 30% discount).
- The cumulative drug-cost savings across the five included countries (Germany, the UK, Italy, the Netherlands, and Belgium) and the six licensed disease areas were projected to range from €25.8 million (10% discount) to €77.4 million (30% discount).
- If such savings made were realized and used to treat additional patients with Remsima, approximately 250 (Belgium, 10% discount) to 2,602 (Germany, 30% discount) additional patients could be treated.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Mundipharma International Ltd. Medical writing assistance for this study was provided by Abacus International . For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. 